4 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow ALK: new trials by email Literature Review of ALK trials Research Report on ALK
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial Bevacizumab combined with iruplinalkib as neoadjuvant therapy in ALK-positive NSCLC: - ALK, NSCLC | Not applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2026-09-15 | 2026-10-13 |
| Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib Iruplinalkib tablets - Non-Small Cell Lung Cancer, ALK | Recruiting | Peking University Shenzhen Hospital | 20 | 2026-01-31 | 2026-01-29 | |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC Ensartinib 225mg, Placebo Ensartinib 225mg - NSCLC Stage III, Ensartinib | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-12-01 | 2025-11-19 |
| The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors Ensartinib group - NSCLC, ALK | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2025-03-15 | 2025-01-13 |
| The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study Group 1 - ALK, NSCLC | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2024-10-30 | 2024-10-22 |
Carcinoma, Non-Small-Cell Lung (2)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Neoadjuvant Therapy (1) · ensartinib (1)
Shanghai Pulmonary Hospital, Shanghai, China (4) · Peking University Shenzhen Hospital (1)
China (1)
PMID 25470694, PMID 27780853, PMID 32418886, PMID 32780660, PMID 35087031, PMID 38384472, PMID 38572751